Ablation therapies are emerging as an innovative way to treat chronic diseases like cancer and cardiovascular diseases. Manufacturers are developing ablation devices based on technologies like radio frequency, robotic-assisted surgeries, electrical, ultrasound and laser, which can destroy targeted or diseased tissues. Ablation devices have become a widely used and critical treatment method for cancer, irregular heartbeats, nerve pain and chronic bronchitis.
The potential of ablation devices is clear, and BCC Research expects the market to continue its growth curve. Estimated at $6.5 billion in 2022, BCC Research expects the market to reach $11.3 billion by 2027, growing at a rate of 11.8% from 2022 through 2027.
With growth on the horizon, technology innovation for ablation devices is rife, and competition is increasing. If one manufacturer develops radio frequency devices to treat arterial walls, another will develop a device that uses electrical energy to treat the same disease. This gives physicians better options for treating their patients because good quality devices with various technological applications are available in the market. Initially, manufacturers relied on thermal technologies such as radiation, light and microwave. The increased competition has also led to innovations as manufacturers invest more in research and development, which has also conducted some new non-thermal technologies, such as cryoablation and hydromechanical.
Changing demographics worldwide is another factor that has led to the evolution of the ablation devices market. The US has a population of nearly 78 million people who were born between 1946 and 1964. This baby boomer population makes up one-third of the country’s population. The global scenario is almost identical to that of the US. The reason for this baby boomer population was a drastic improvement in the fertility rate in the US, Europe and some other countries such as Australia and New Zealand. According to the US Census Bureau, by 2030, all boomers will be aged at least 65. Minimally invasive ablation therapies are better treatment options for the fragile and aging bodies of the baby boomer population. Manufacturers have kept this factor in mind and are developing ablation therapies for this aging population.
Technological advancement in ablation devices leads to cost-effective, innovative products that offer better treatment facilities for physicians and patients. The ablation devices market’s many innovations, such as radio frequency in thermal technologies and cryoablation in nonthermal technologies, are driving forces for the market, and the trend is expected to continue.
Technological advancements in radio frequency ablation (RFA) clinical experiments are initially carried out on animals, and upon successful implementation, they are used on human beings.